What are TLR7 agonist drugs?

TLR7 agonist drugs are pharmacologic agents that share a common mechanism (typically targeting TLR7 (Toll-like receptor 7)). 2 are currently marketed, with 5 more in clinical development.

What are the marketed TLR7 agonist drugs?

Marketed TLR7 agonist drugs include Aldara (imiquimod) cream, 5%, Imiquimod 3.75% Cream.

TLR7 agonist

2 marketed 4 in Phase 3 1 in Phase 2

This page covers all TLR7 agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting TLR7 (Toll-like receptor 7), TLR7.

Targets

TLR7 (Toll-like receptor 7) · TLR7

Marketed (2)

Aldara (imiquimod) cream, 5% · Graceway Pharmaceuticals, LLC · Oncology, Dermatology, Immunology
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions and certain cancers.
Imiquimod 3.75% Cream · Medical University of Graz · Dermatology/Oncology
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions.

Phase 3 pipeline (4)

Aldara (Imiquimod) · MEDA Pharma GmbH & Co. KG · Dermatology, Oncology, Immunology
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat viral infections and skin cancers.
Imiquimod 5%: manufactured by Apotex · Apotex Inc. · Dermatology, Oncology, Immunology
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions and certain cancers.
Topical Imiquimod · Medical University of Vienna · Dermatology/Oncology
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local antiviral and antitumor immunity.
IV Tulisokibart · Merck Sharp & Dohme LLC · Oncology
Tulisokibart is a TLR7 agonist that activates innate immune responses to enhance anti-tumor immunity.

Phase 2 pipeline (1)

EL219 · Elion Therapeutics, Inc. · Oncology
EL219 is an immunostimulatory agent designed to activate innate immune responses against cancer.